Salihoglu Ayse, Ar Muhlis Cem, Soysal Teoman
a Department of Internal Medicine, Division of Haematology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey.
Expert Rev Hematol. 2015 Dec;8(6):765-83. doi: 10.1586/17474086.2015.1091301. Epub 2015 Sep 28.
B-cell lymphoproliferative disorders comprise 85% of Non-Hodgkin's lymphomas. Despite successful chemoimmunotherapy regimens, responses are not durable and the outcome is fatal in a considerable portion of patients. There is an inevitable need for less toxic and more potent therapeutic agents. Over the recent years, a plethora of agents including monoclonal antibodies, Bcl-2 antagonists, tyrosine kinase inhibitors, cyclin-dependent kinase inhibitors, mTOR inhibitors and immunomodulatory drugs have been developed in B-cell malignancies. The aim of this paper is to focus on B-cell receptor signaling inhibitors and lenalidomide as an immunomodulatory drug and to provide insight on how and when to incorporate these agents into the treatment algorithms.
B细胞淋巴增殖性疾病占非霍奇金淋巴瘤的85%。尽管有成功的化疗免疫治疗方案，但反应并不持久，相当一部分患者的结局是致命的。不可避免地需要毒性更小、效力更强的治疗药物。近年来，在B细胞恶性肿瘤中已开发出大量药物，包括单克隆抗体、Bcl-2拮抗剂、酪氨酸激酶抑制剂、细胞周期蛋白依赖性激酶抑制剂、mTOR抑制剂和免疫调节药物。本文的目的是聚焦于B细胞受体信号传导抑制剂和作为免疫调节药物的来那度胺，并深入探讨如何以及何时将这些药物纳入治疗方案。
